Regulus hep C combination drug effective in mid-stage study

(Reuters) - Regulus Therapeutics Inc said interim data showed that patients tested with its hepatitis C drug combination treatment displayed sustained viral response in an ongoing mid-stage study, sending its shares up 43 percent in premarket trading.

http://ift.tt/1U7Hr9M

from Reuters: Health News
via animenewspro